Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Monomethyl Fumarate Prodrug
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable
MYT-109, a Promising Treatment for Leigh Syndrome
Details : MYT-109 improves mitochondrial functions and rescues lethality in animal models of Leigh’s Syndrome. It’s a prodrug, using a proprietary technology, with improved PK compared to other fumarate based drugs.
Product Name : MYT-109
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Monomethyl Fumarate Prodrug
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
